Protara Therapeutics, Inc. (TARA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New York City, NY, United States. The current CEO is Jesse Shefferman.
TARA has IPO date of 2014-10-22, 28 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $197.96M.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
